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In vitro secretion of cytokines and
prostaglandin-E2 by monocytes from lung
cancer patients
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Monocytes (MO) from cancer patients present functional abnormalities, such as an altered secretion of soluble
factors. In the present study, our aim was to evaluate the levels of interleukin-1b (IL-1b), tumour necrosis factor-
alpha (TNF-a) and prostaglandin-E2 (PGE2) secreted in vitro by MO from lung cancer patients (LCP),
spontaneously or after stimulation with lipopolysaccharide (LPS). Results showed that cytokine secretion was
higher for MO from LCP than for MO from healthy controls, while in the 25% of the patients analysed, an absence
of response to LPS treatment was found.
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There is increasing evidence that tumour burden seems to
affect the activity of the immunological system of the host,
altering the normal function of mononuclear cells (1,2).
Particularly, it has been demonstrated that the tumour
micro-environment found in lung carcinomas acts as an
activator of monocytes (MO), compared to lymphoid tissue
of tumour-free lung (3). The secretion of cytokines like
interleukin-1 (IL-1) and tumour necrosis factor-a (TNF-a)
(4,5), as well as the production of oxygen radicals (6), are
known to be affected.
The alterations found in MO from cancer patients can
also involve some phenotypic aspects. In a previous work,
our laboratory reported that MO from cancer patients
showed a diminished percentage of HLA-DR expression
compared to those of healthy controls (7,8). In this report,
we show that freshly isolated MO from LCP exhibit
changes in their capacity of secreting soluble factors, such
as IL-1, TNF-a and PGE2, either spontaneously (sp) or
upon stimulation with lipopolysaccharide (LPS), a known
activator of MO functions (9).Received 3 April 2000 and accepted in revised form 30 October
2000.
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PATIENTS
Twelve patients with lung epidermoid carcinomas (LCP),
clinical stages III and IV, who had not undergone
chemotherapy treatment were included in this study. MO
from 12 healthy donors were used as controls (HC).
ISOLATION OF PERIPHERAL BLOOD
MONONUCLEAR CELLS (PBMCs)
Blood from patients and controls was obtained by venous
puncteon and anti-coagulated with EDTA 2?8%. Samples
were diluted with phosphate-buffered saline, Ca27/Mg2+-
free (PBS), and PBMC isolated by means of a Ficoll–
Hypaque gradient (density 1076Hgml71). Cells harvested
from the interface were washed three times and resuspended
in complete medium (CM): RPMI-1640 medium, contain-
ing 10% of heat inactivated fetal calf serum and 1%
antibiotic-antimicotic (Gibco BRL, Gaithesburg, MD,
U.S.A.).
ISOLATION OF MO
Samples containing 26106 PBMC well71 were seeded in
24-well plastic plates (Nunc Inc., Naperville, IL, U.S.A.)
and incubated for 1 h at a 378C in a humified atmosphere.
Non-adherent cells were removed by washing with CM.
Monotype content in adherent cells (greater than 90%) was# 2001 HARCOURT PUBLISHERS LTD
FIG. 1 Levels of in vitro secretion of IL-1, TNF-a and
PGE2 by monocytes from lung cancer patients (LCP) and
healthy controls (HC). sp: spontaneous secretion; LPS:
secretion after stimulation with LPS. *P50?05 vs. sp;
**P50?0001 vs. sp; ***P50?01 vs. sp HC; #P50?05 vs.
sp. &: LCP; &: HC.
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body (anti-CD13, Dako Corp., Carpinteria, CA, U.S.A.)
and an alkaline phosphatase–anti-alkaline phosphatase
technique.
Monocytes were incubated in CM with or without
10 mgml71 of LPS (Sigma Chemical Co. St Louis, MO,
U.S.A.). After 24 h, supernatants were withdrawn, centri-
fuged at 500 g for 10min and stored at 7208C, (or at
7708C in the case of PGE2 assay), until use. Prior to being
assayed, supernatants were diluted in RPMI-1640 medium.
CYTOKINE QUANTIFICATION
Levels of PGE2 in supernatants (1:10 diluted) were
determined by RIA using a commercial kit (Prostaglandin
E2-[I125] Nen Research Products, DuPont Corp, Boston,
MA, U.S.A.). Sensitivity of the assay: 2?5–250 pgml71.
TNF-a and IL-1 (1:5 diluted) were quantified by ELISA
commercial kits (DuPont). Sensitivity of the assay:
10–1000 pgml71.
STATISTICAL ANALYSIS
Statistical analysis was performed by unpaired Student’s
t-test. Results were considered significant at the P50?05
level.
Results and discussion
In spite of the widely documented observation that MO
from LCP present functional abnormalities (10–12), the
exact cause for a defective production of cytokines is still
unknown. In the present study, MO obtained from LCP
secrete higher levels of IL-1 than controls [Fig. 1:
sp169?2+97?2, LPS546?0+151?6 (P50?05 vs. sp);
HC: sp72?5+25?0, LPS357?6+36?4 (P50?0001 vs.
spontaneous secretion; sp), mean+standard error, in
pgml71]; this could be attributed to the presence of the
tumour itself, acting as a non-specific activator of the host’s
immune response (13). Although this result is in agreement
with those obtained by Farin˜as et al. (14), other authors did
not find differences in the levels of IL-1b secreted by LCP
and controls. However, in the latter case, cytotoxic activity
was lower in MO, suggesting discrepancies between anti-
tumoral and secretory capacities (15).
Evidence in the literature suggests that the anti-tumoral
activity in peritoneal macrophages is related to an increase
of TNF-a, and a decrease in PGE2 production (16). In this
study we report elevated levels of TNF-a spontaneously
secreted by LCP MO, with figures over 800 pg ml71 in
three patients [LCP: sp452?6+107?2 (P50?01 vs. sp HC),
LPS589?5+126?7 (n.s.); HC: sp72?4+21?5, LPS573?5
+87?1 (P50?0001 vs. sp)]. At the same time, no differences
were found in the spontaneous secretion of PGE2 between
patients and controls [LCP: sp=56?4+7?6 LPS=119?7+
26?3, (P50?05 vs. sp and LPS HC) HC : sp=49?8+6?5,
LPS=198?3+16?8 (P50?0001 vs. sp)].How could the opposite behaviours in PGE2 and TNF-a
secretion be explained? One possibility could be that
tumour cells themselves may be secreting PGE2, which,
through a feedback mechanism, affects PGE2 secretion by
MO. Huang et al. (17) reported that non-small-cell lung
cancer cells secrete PGE2, which has an effect on peripheral
blood lymphocyte functions. Previous work from our
laboratory showed that culture supernatants from lung
cancer cell lines exert functional and phenotypic alterations
in normal MO which can also be found in MO from LCP.
Such changes include a diminished percentage of HLA-DR,
a reduction of phagocytic capacity and an incremented
NBT reduction capacity (18). Thus, the elevated levels of
spontaneous secreted TNF-a could be a consequence of a
decrease in PGE2 production. As a matter of fact, an
incremented production of TNF-a correlated to low levels
of PGE2 production, has been observed in MO from
bladder cancer in advanced stages (19). Additionally, PGE2
has been shown to inhibit TNF-a release (20).
It is noteworthy that in the 25% of the patients analysed
in this study, PGE2, TNF-a and IL-1 secretion values after
LPS stimulation were lower than the respective sponta-
neous values, indicating a lack of MO response to LPS. A
soluble factor could be acting as an inhibitor of the process
of MO activation by LPS. It is well known that some
cytokines, like IL-6, exert this kind of inhibitory effect both
in vivo and in vitro (21). Alternatively, the LPS activation
pathway could be affected at the molecular level, and/or
certain enhancer elements, needed for LPS induction of
TNF-a synthesis (22) could be non-functional. Interest-
ingly, this lack of response was not observed in MO
obtained from colorectal cancer patients (unpublished data)
revealing differences in the immune response induced by
tumours arising in different tissues.
Research in this area will continue in our laboratory,
hoping that further studies on the role of monocytes in
CYTOKINES AND PROSTAGLANDIN-E2 BY MONOCYTES 245tumour progression should provide a deeper insight into
clinical immunotherapy.
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